Literature DB >> 26176734

Salvianolic acid A reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2.

Xiaowei Zheng1, Siying Chen1, Qianting Yang1, Jiangxia Cai2, Weipeng Zhang1, Haisheng You1, Jianfeng Xing3, Yalin Dong1.   

Abstract

Multidrug resistance and tumor migration and invasion are the major obstacles to effective breast cancer chemotherapy, but the underlying molecular mechanisms remain unclear. This study investigated the potential of transgelin 2 and salvianolic acid A to modulate the resistance and the migration and invasion abilities of paclitaxel-resistant human breast cancer cells (MCF-7/PTX). MCF-7/PTX cells were found to exhibit not only a high degree of resistance to paclitaxel, but also strong migration and invasion abilities. Small interfering RNA-mediated knockdown of TAGLN2 sensitized the MCF-7/PTX cells to paclitaxel, and inhibited their migration and invasion abilities. In addition, we also observed that combined salvianolic acid A and paclitaxel treatment could reverse paclitaxel resistance, markedly inhibit tumor migration and invasion, and suppress the expression of transgelin 2 in MCF-7/PTX cells. These findings indicate that salvianolic acid A can reverse the paclitaxel resistance and inhibit the migration and invasion abilities of human breast cancer cells by down-regulating the expression of transgelin 2, and hence could be useful in breast cancer treatments.

Entities:  

Keywords:  breast cancer; invasion; migration; paclitaxel resistance; salvianolic acid A; transgelin 2

Mesh:

Substances:

Year:  2015        PMID: 26176734      PMCID: PMC4622441          DOI: 10.1080/15384047.2015.1070990

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  35 in total

1.  Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2.

Authors:  Jiangxia Cai; Siying Chen; Weipeng Zhang; Sasa Hu; Jun Lu; Jianfeng Xing; Yalin Dong
Journal:  Phytomedicine       Date:  2014-03-26       Impact factor: 5.340

2.  Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway.

Authors:  Jiangxia Cai; Siying Chen; Weipeng Zhang; Xiaowei Zheng; Sasa Hu; Chengsen Pang; Jun Lu; Jianfeng Xing; Yalin Dong
Journal:  Phytomedicine       Date:  2014-09-17       Impact factor: 5.340

3.  Salvianolic acid A shows selective cytotoxicity against multidrug-resistant MCF-7 breast cancer cells.

Authors:  Xin Wang; Chunyan Wang; Longjiang Zhang; Yanjun Li; Shouju Wang; Jiandong Wang; Caiyun Yuan; Jia Niu; Chengsheng Wang; Guangming Lu
Journal:  Anticancer Drugs       Date:  2015-02       Impact factor: 2.248

4.  GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.

Authors:  Tian Huanna; Zuo Tao; Wang Xiangfei; An Longfei; Xie Yuanyuan; Wang Jianhua; Zhang Cuifang; Jiao Manjing; Cao Wenjing; Qin Shaochuan; Xu Feifei; Li Naikang; Zhang Jinchao; Wu Chen
Journal:  Mol Carcinog       Date:  2014-06-24       Impact factor: 4.784

Review 5.  The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells.

Authors:  Huiying Liu; Xiaofeng Zhang; Jun Li; Bin Sun; Haihua Qian; Zhengfeng Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

6.  Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness.

Authors:  Shuqin Li; Yan Xie; Wei Zhang; Junfeng Gao; Man Wang; Guoxuan Zheng; Xing Yin; Hongping Xia; Xiang Tao
Journal:  J Surg Res       Date:  2014-07-05       Impact factor: 2.192

7.  Salvianolic acid A, a matrix metalloproteinase-9 inhibitor of Salvia miltiorrhiza, attenuates aortic aneurysm formation in apolipoprotein E-deficient mice.

Authors:  Tingting Zhang; Jinghua Xu; Defang Li; Jing Chen; Xu Shen; Feng Xu; Fukang Teng; Yanping Deng; Hongmei Ma; Li Zhang; Ge Zhang; Zhou Zhang; Wanying Wu; Xuan Liu; Min Yang; Baohong Jiang; Den Guo
Journal:  Phytomedicine       Date:  2014-06-07       Impact factor: 5.340

8.  Cloning and sequencing of cDNAs encoding the actin cross-linking protein transgelin defines a new family of actin-associated proteins.

Authors:  R K Prinjha; C E Shapland; J J Hsuan; N F Totty; I J Mason; D Lawson
Journal:  Cell Motil Cytoskeleton       Date:  1994

9.  Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer.

Authors:  Haiji Wang; Chunyuan Xu; Xiaoli Kong; Xiaoyan Li; Xiangnan Kong; Yu Wang; Xia Ding; Qifeng Yang
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

10.  CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway.

Authors:  Mingde Zang; Baogui Zhang; Yunqiang Zhang; Jianfang Li; Liping Su; Zhenggang Zhu; Qinlong Gu; Bingya Liu; Min Yan
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

View more
  16 in total

1.  Salvianolic acid A inhibits tumor-associated angiogenesis by blocking GRP78 secretion.

Authors:  Yufei Yang; Lichao Zhang; Xiaoqin La; Zhuoyu Li; Hanqing Li; Songjia Guo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-17       Impact factor: 3.000

Review 2.  Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms.

Authors:  Huan Zhao; Bing Han; Xuan Li; Chengtao Sun; Yufei Zhai; Man Li; Mi Jiang; Weiping Zhang; Yi Liang; Guoyin Kai
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

3.  Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.

Authors:  Tingting Ye; Rongrong Chen; Yu Zhou; Juan Zhang; Zhongqin Zhang; Hui Wei; Yan Xu; Yulan Wang; Yinlan Zhang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus patients.

Authors:  Kaori Kiso; Hajime Yoshifuji; Takuma Oku; Masaki Hikida; Koji Kitagori; Yoshitaka Hirayama; Toshiki Nakajima; Hironori Haga; Tatsuaki Tsuruyama; Aya Miyagawa-Hayashino
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

5.  Salvianolic Acid A, as a Novel ETA Receptor Antagonist, Shows Inhibitory Effects on Tumor in Vitro.

Authors:  Qiao Zhang; Shifeng Wang; Yangyang Yu; Shengnan Sun; Yuxin Zhang; Yanling Zhang; Wei Yang; Shiyou Li; Yanjiang Qiao
Journal:  Int J Mol Sci       Date:  2016-08-02       Impact factor: 5.923

6.  SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells.

Authors:  Xiaowei Zheng; Changwei Wang; Yuanming Xing; Siying Chen; Ti Meng; Haisheng You; Iwao Ojima; Yalin Dong
Journal:  Int J Oncol       Date:  2017-02-10       Impact factor: 5.650

7.  Some pharmacokinetic parameters of salvianolic acid A following single-dose oral administration to rats.

Authors:  Jialin Sun; Junke Song; Wen Zhang; Fanbo Jing; Wen Xu; Ping Leng; Xianghua Quan; Guanhua Du; Zhongguo Sui
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

8.  Systematic Understanding of the Mechanism of Salvianolic Acid A via Computational Target Fishing.

Authors:  Shao-Jun Chen; Ming-Chao Cui
Journal:  Molecules       Date:  2017-04-17       Impact factor: 4.411

9.  Penfluridol overcomes paclitaxel resistance in metastatic breast cancer.

Authors:  Nehal Gupta; Parul Gupta; Sanjay K Srivastava
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

Review 10.  Salvianolic Acids: Potential Source of Natural Drugs for the Treatment of Fibrosis Disease and Cancer.

Authors:  Lunkun Ma; Liling Tang; Qian Yi
Journal:  Front Pharmacol       Date:  2019-02-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.